A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity

NCT03954106 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
25
Enrollment
INDUSTRY
Sponsor class

Stopped Primary endpoint would unlikely to be met based on the unplanned interim assessment on the first 20 efficacy evaluable patients.

Conditions

Interventions

Sponsor

Jazz Pharmaceuticals